

Resource Summary Report

Generated by [NIF](#) on Aug 30, 2026

B16-F10

RRID:CVCL_0159

Type: Cell Line

Proper Citation

KCLB Cat# 80008, RRID:CVCL_0159

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0159

Proper Citation: KCLB Cat# 80008, RRID:CVCL_0159

Description: Cell line B16-F10 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Male

Disease: Mouse melanoma

Defining Citation: [PMID:210294](#), [PMID:1109790](#), [PMID:6539703](#), [PMID:11833741](#), [PMID:23890195](#), [PMID:25277546](#), [PMID:30084848](#)

Comments: Characteristics: Has a high metastatic potential., Characteristics: Obtained from the pulmonary melanoma module of the 10th serial passage of the B16-F0 parent cell line in C57BL/6 mice.

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: B16-F10

Synonyms: B16/F10, B16 F10, B16F10, B16 melanoma F10

Cross References: BTO:BTO_0002014, CLO:CLO_0001794, CLO:CLO_0050763, EFO:EFO_0022759, MCCL:MCC:0000051, CLDB:cl339, CLDB:cl4967, AddexBio:C0012005/5003, ATCC:CRL-6475, BCRC:60031, BCRJ:0046, BioGRID_ORCS_Cell_line:737, CCRID:1101MOU-PUMC000473, CCRID:3101MOUTCM36, CCRID:6101MOU-CERC000106, ChEMBL-Cells:ChEMBL3307762, ChEMBL-Targets:ChEMBL612656, CLS:305157, ICLC:ATL99010, KCB:KCB 2014047YJ, KCLB:80008, Lonza:998, NCBI_Iran:C540, NCI-DTP:B16F10, PRIDE:PX008733, PubChem_Cell_line:CVCL_0159, RCB:RCB2630,

TKG:TKG 0348, Ubigene:YC-A011, Wikidata:Q54752438

ID: CVCL_0159

Vendor: KCLB

Catalog Number: 80008

Hierarchy: cvcl_uj41

Record Creation Time: 20220427T215231+0000

Record Last Update: 20260830T002309+0000

Ratings and Alerts

No rating or validation information has been found for B16-F10.

No alerts have been found for B16-F10.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 3937 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

Qiao L, et al. (2026) A Natural Sweetener-inducible Genetic Switch Controls Therapeutic Protein Expression in Mammals. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e14226.

Smits D, et al. (2026) Glycocalyx micro- and nanodomains in cell-cell and cell-matrix interactions revealed by enhanced click chemistry. Nature communications, 17(1).

Chen S, et al. (2026) 16-h fasting optimizes cancer immunotherapy in mice and humans. Cell metabolism, 38(5), 944.

Yang Y, et al. (2026) Oncolytic virotherapy potentiates chemo-PD-1 immunotherapy by engaging chemo-resistant bystander CD8+ T cells. Journal for immunotherapy of cancer, 14(3).

Pan D, et al. (2026) DGAT1 Inhibition Induces Ferroptosis and Enhances Cancer Immunotherapy Efficacy. Cancer research, 86(12), 3026.

Yang Q, et al. (2026) MSH6 regulates cGAS activity in antiviral and antitumor signaling pathways by governing its cytosolic/nuclear distribution. Cell reports, 45(3), 117059.

Maltez VI, et al. (2026) Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment. *Immunity*, 59(4), 1058.

Li Y, et al. (2026) Tumor-Intrinsic ARHGEF3 Enhances Antitumor Immunity by Promoting T-Cell Infiltration and Limiting Myeloid Cell-Mediated Immunosuppression. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(38), e23895.

Sun Y, et al. (2026) Discovery of TYR inhibitors from de novo molecular generation to dual-track lead optimization: "Competition" between AI and chemists. *Science advances*, 12(25), eaeg0376.

Xiong T, et al. (2026) Small-Molecule Boron-10-Enriched Carriers with Exceptional Aqueous Solubility for Enhanced Boron Neutron Capture Therapy of Malignant Tumors. *Research* (Washington, D.C.), 9, 1315.

Jiang H, et al. (2026) IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy. *Immunity*, 59(1), 177.

Kou X, et al. (2026) Tumor-activated dual metabolic nanomodulator turns over tolerogenic tumor control and unleashes systemic immune responses. *Journal of nanobiotechnology*, 24(1).

Feng Q, et al. (2026) Targeting severe acidity for tumor-activatable Interleukin-2 therapy. *Cell reports. Medicine*, 7(1), 102572.

Obenaus M, et al. (2026) T cell engagers control solid tumors through clonal replacement and IL2-driven effector differentiation of CD8 T cells. *bioRxiv : the preprint server for biology*.

Marco S, et al. (2026) Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity. *Cancer cell*, 44(5), 995.

Zitti B, et al. (2026) Positioning and reversible suppression of CCR7+ dendritic cells in perivascular tumor niches shape cancer immunity. *Immunity*, 59(1), 161.

Hu Y, et al. (2026) Irradiated Tumor Cell-Derived Microparticles Activate Systemic Anti-Tumor Immunity via the STING/NLRP3/GSDMD Axis in Neutrophils. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e14390.

Chen X, et al. (2026) Dopaminergic modulation of NK cell maturation and immune-associated social behavior in a 15q dup mouse model. *Brain, behavior, and immunity*, 135, 106527.

Liu Y, et al. (2026) Immunogenic tumor cell death and T-cell-derived IFN- γ elicit tumoricidal macrophages to potentiate OX40 immunotherapy. *Cell reports. Medicine*, 7(4), 102699.

Li S, et al. (2026) Rationally designed light-inducible RNA-releasing protein for translational regulation and optogenetic control of gene therapies. *Trends in biotechnology*.